Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Lantheus Holdings was founded in 1985 and began operations in 2000. In 2003, Lantheus acquired its first imaging agent, ProHANCE. Since then, it has expanded its product offering to include two other products, DEFINITY and TechneLite. It also holds the licenses to manufacture and market additional products worldwide.
Our mission is to be a leader in diagnosing and providing life-saving treatments to millions of people around the world with our imaging agents and products.
Our vision is to be the world's leading imaging agent and product provider, helping healthcare providers diagnose and treat patients with life-saving treatments precisely and effectively.
Mr. Daniel M. Niedzwiecki (Sr. VP, Gen. Counsel & Corp. Sec.)
Mr. Etienne Montagut (Chief Bus. Officer)
Ms. Andrea Sabens (Chief Accounting Officer)
Ms. Dorothy Barr (Sr. VP of Manufacturing & Technical Operations)
Mr. Mark Richard Kinarney (Sr. Director of Investor Relations)
Ms. Linda S. Lennox (VP of Corp. Communications & Chief of Staff)
Melissa Downs (Director of Corp. Communications)
Recognition and Awards
Lantheus has received numerous awards over the years for its innovative products, including the 2016 Breakthrough Award for Outstanding Innovation in Imaging from the International Imaging Association and the 2015 Outstanding Medical Imaging Industry Achievement Award from Frost & Sullivan.